Business Wire

Takeda Reports Results for Three Quarters (April-December) of FY2015,Reaffirms Management Guidance for the Full Year


Takeda Pharmaceutical Company Limited (TOKYO:4502):

Results of April to December period reaffirms full-year management guidance

  • Underlying revenue +3.8% year-to-year (reported revenue growing +4.0% to 1,393.3 billion yen), led by strong performance in the U.S. and the emerging markets
  • Underlying Core Earnings +1.5% year-to-year (operating profit -15.9% to 167.5 billion yen)
  • Underlying Core EPS +17.3% year-to year (reported EPS growing +43% to 145 yen)

Contribution of Takeda's growth drivers

  • Consolidated underlying revenue of gastroenterology, oncology and emerging markets – Takeda's growth drivers – is +8.5% year-to-year
  • Gastroenterology underlying revenue +24.7%, oncology up +0.4% year-to-year
  • Emerging markets underlying revenue +5.7% year-to-year, with particularly strong contributions from Russia and China

Growth of innovative new products to offset loss of exclusivity impact

  • ENTYVIO® is on the way to over $2 bln in peak sales, BRINTELLIX® and ADCETRIS® show steady growth
  • AZILVA® and LOTRIGA® are contributing to Japan business.

Efficiency gains continue

  • Project Summit achieved 21 billion yen of cost savings in the April-December 2015 period, exceeding the full-year target

For FY2015 full year reported forecast, operating profit upgraded, others unchanged

  • Based on performance through three quarters, Takeda raised the full year reported forecast for operating profit to 120 billion yen

Affirming management guidance in FY2015

  • Low single-digit underlying revenue growth in FY2015, with underlying core earnings growth higher than underlying revenue growth, and underlying core EPS growth higher than underlying core earnings growth

Christophe Weber, President and Chief Executive Officer of Takeda, commented:
"Through three quarters (April to December) of FY2015, Takeda's turnaround continues, with underlying revenue growth of +3.8% year-to-year, led by our growth drivers of gastroenterology, oncology and emerging markets. With the global launch of new products such as ENTYVIO and NINLARO, Takeda is on the right track to deliver revenue growth and improved profitability. On the basis of our three quarters results, we confirm our full-year management guidance."

Key figures for three quarters


of FY2015

  FY 2014   FY 2015   Growth
billion yen Apr-Dec Apr-Dec     Underlying2
Revenue 1,340.0 1,393.3 +4.0% +3.8%
Operating Profit 199.1 167.5 -15.9%
Core Earnings 1 276.5 269.8 -2.4% +1.5%
Net Profit 3 79.7 113.6 +42.5%
EPS 101 yen 145 yen +43.0%
Core EPS   216 yen   241 yen   +11.4%   +17.3%


  Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs.


Underlying performance aims at understanding the real performance of the business. Underlying Revenue and Underlying Core Earnings excludes the same as above and adjusted for acquisitions/divestments and foreign exchange.


Attributable to the owners of the company

Underlying revenue growth in the 3Q (April to December, 2015) was +3.8% year-to-year, Underlying Core Earnings was +1.5% and Underlying Core EPS was +17.3%, with no change in Takeda's management guidance for FY2015. Reported revenue grew +4.0% year-to-year to 1,393.3 billion yen. An increase in expenses to new global products as well as a decrease in other income such as reversal of COLCRYS® contingent consideration and gain from sales of real estate in 2014, resulted in a year-to-year decline in Operating Profit by 31.6 billion yen. Despite the decrease in operating profit, consolidated net profit was 113.6 billion yen, an increase of 33.9 billion yen (+42.5% year-to-year), mainly due to the decrease in income tax expenses.

Underlying revenue growth was mainly driven by Takeda's growth drivers; gastroenterology, oncology and emerging markets. The three account for almost 50% of Takeda's revenue. Gastroenterology grew by +24.7% year-to-year, driven by ENTYVIO®. Oncology revenue, including VELCADE® and ADCETRIS®, increased by +0.4%. Launched in the U.S. in December, NINLARO®, a highly innovative once-weekly capsule for multiple myeloma, is expected to provide a significant contribution to Takeda's mid- to long-term sustained growth. Emerging Markets revenue grew by +5.7% year-to-year, led by Value Brands (branded generics and Over-The-Counter medicines), with strong growth in Russia and China. Performance in the U.S. (+11.6% year-to-year underlying revenue growth) also contributed to revenue growth. In Japan, under the increasing generic pressure, underlying revenue declined -1.7% year-to-year, but the year-to-year revenue declines moderated, led by the contribution of AZILVA® and LOTRIGA®.

Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 21 billion yen savings in the three quarters period, exceeding the full year target.

ENTYVIO® and NINLARO® are expected to be key global contributors to Takeda's sales growth. In Japan, a new business venture with Teva Pharmaceutical Industries Ltd. will be established in or after April 2016 to deliver Teva's high-quality generic medicines and Takeda's long-listed products to patients. It is expected to meet wide-ranged needs of patients and correspond to the growing importance of generics in Japan, while Takeda will further focus on innovative new medicines, such as AZILVA®, LOTRIGA®, TAKECAB®, NESINA® and ZAFATEK®.

As part of its ongoing effort to improve the R&D productivity, Takeda announced that its top priority is to be a leader in three therapeutic areas, Oncology, Gastroenterology and Central Nervous System. In addition, it will deliver maximum, targeted value in Specialty CV and an innovative business and global health approach in Vaccines.

Takeda affirmed its management guidance for FY2015, leading to long-term sales and profit growth, and raised the full-year reported forecast of operating profit to 120 billion yen, based on the three quarters' results.

Management Guidance for FY2015

  Underlying Growth
Underlying Revenue Low single digit
Underlying Core Earnings Higher than underlying revenue growth
Underlying Core EPS   Higher than underlying core earnings growth

FY2015 full year reported


forecast: operating profit revised, others unchanged

billion yen Previous


  Change   Revised


Revenue 1,820.0 1,820.0
R&D expenses 330.0 330.0
Operating profit 105.0 +15.0(+14.3%) 120.0
Profit before tax 115.0 115.0
Net profit for the year 68.0 68.0
EPS   87 yen     87 yen

For more details on Takeda’s FY2015 3Q results and other financial information, please visit

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Information about Takeda is available on

Contact information

Takeda Pharmaceutical Company Limited
Investor Relations
Noriko Higuchi, +81-(0)3-3278-2306
Media Relations
Japanese media
Tsuyoshi Tada, +81 (0)3-3278-2417,
Media outside Japan
Jocelyn Gerst, +1-224-554-5542

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

LIAF: Experts at the European Parlament - E-Cigarettes Are a Potential Game Changer for European Health20.3.2018 18:27Pressemelding

The following is a statement from LIAF – Lega Italiana Anti Fumo: The panel discussion at the EU Parliament recognises the potential benefits of electronic cigarettes and for European countries to treat these products as regular consumer products to ensure equal access for all Europeans. Following a debate in which leading scientific experts presented the state-of-the-art evidence around e-cigarettes, it became clear that public health is increasingly moving on from an approach that solely advocates ‘quit-or-die’ to a harm reduction strategy. “I’m glad to have brought the Parliament attention to this important issue for public health. Today we have listened to the results of scientific studies and researches from a high-level expert’s roundtable, which have illustrated to us the advantages of electronic cigarettes and the potential public health benefits that these products pose when compared to the conventional cigarettes. As decision-makers, we need to take into considerations these

Morinaga Milk's New Probiotic Strain, Bifidobacterium breve A1, May Prevent Onset of Alzheimer's Disease20.3.2018 18:00Pressemelding

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced the results of a new study investigating the preventive effects of its new probiotic strain Bifidobacterium breve A1 on a model of Alzheimer’s disease. Researchers found that B. breve A1 improved spatial recognition capability, as well as learning and memory capabilities, in cognitively deficient mice, indicating it could play an important role in preventing the onset of Alzheimer’s Disease in humans.1 This press release features multimedia. View the full release here: (Fig. 1) Effects of B. Breve A1 in improving spatial recognition, learning and memory capabilities (Graphic: Business Wire) The number of patients affected by dementia is increasing worldwide. One report estimates there were 46.8 million people worldwide living with dementia in 2015 and projects this number will reach 131.5 million by 2050.2 Alzheimer’s disease

Dubai Breaks Ground on World’s Biggest CSP Project20.3.2018 16:10Pressemelding

HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, broke ground on the 4th phase of the Mohammed bin Rashid Al Maktoum Solar Park. This is the biggest Concentrated Solar Power (CSP) investment project in the world, based on the Independent Power Producer (IPP) model, and will generate 700MW on a single site. It will have the world’s tallest solar tower at 260 metres, and the largest thermal energy storage capacity in the world. It will provide clean energy to 270,000 residences, reducing 1.4 million tonnes of carbon emissions annually. The project will use two technologies: a 600MW parabolic basin complex and a 100MW solar tower, over 43 square kilometres. This project, with AED14.2 billion in investments, achieved the lowest Levelised Cost of Electricity (LCOE) of USD 7.3 cents per kW/h. This press release features multimedia. View the full release here: Dubai breaks groun

Edgecore Networks Introduces 400G Open Networking20.3.2018 16:00Pressemelding

OCP Summit – Edgecore Networks, the leader in open networking, today announced its contribution to the Open Compute Project (OCP) of the design of a 400 Gigabit Ethernet (400G) data center switch, the industry’s first 400G open design, that will enable public and private network operators to increase dramatically the capacity of their infrastructures. “Four years ago, Edgecore contributed the industry’s first OCP-ACCEPTED™ network product, a 10G top-of-rack switch,” said George Tchaparian, CEO, Edgecore Networks. “Since then, we have contributed over 15 network product designs as open networking technology and deployments grew to include 25G/100G data center fabrics, deep-buffer data center interconnect switches, service provider access infrastructures, open modular chassis, and campus/branch/wireless networks. Now, Edgecore is introducing the industry’s first 400G open network switch, enabling network operators to respond to growing demands for network capacity, and increasing the ban

Technics Organizes World's First Full Turntable Orchestra20.3.2018 14:48Pressemelding

On March 20, 2018, the "Record Day," Panasonic Corporation released the video of the world's first full orchestra performance featuring Technics "turntables (analog record players)" as the only instruments, under the Technics brand's theme, "Rediscover Music." This press release features multimedia. View the full release here: World's First Full Turntable Orchestra organized by Technics (Photo: Business Wire) Videos: - THE PHILHARMONIC TURNTABLE ORCHESTRA - BEHIND THE BEATS : THE PHILHARMONIC TURNTABLE ORCHESTRA "The Philharmonic Turntable Orchestra" special website Thirty renowned DJs from around the world, including DJ Rena, the reigning Japanese world champion (youngest ever world champion in history), who took the "DMC World Championship" title in 2017 at just 12 years old*, came together to create the world's first "turntable orchestra." Using the Technics' iconic tu

Bentley Systems' Year in Infrastructure 2018 Conference and Awards Gala to be Held in London, Oct. 15-1820.3.2018 14:30Pressemelding

Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, today announced that the Year in Infrastructure 2018 Conference will be held Oct. 15 through 18 in London at the Hilton London Metropole. Presented by Bentley Institute, the conference is a global gathering of leading industry executives and prominent thought leaders in the design, construction, and operations of the world’s infrastructure. The theme of this year’s conference is Going Digital: Advancements in Infrastructure. The conference features nearly 70 speakers and more than 50 informative sessions, including keynotes by leading industry experts, interactive workshops, forums, panel discussions, and product demonstrations. Attendees can visit the Technology Pavilion, which features exhibits and presentations from Bentley Systems and its strategic partners Microsoft, Siemens, Topcon, and Bureau Veritas. On the first day of the conference, Bentley Institute wil